PP 1505(7767)/09/2008(010132)

Corporate Highlights

News Update



31 January 2008

Share Price Fair Value	:	RM3.00 RM4.04
Recom	:	Outperform
		(maintained)

Hai-O Enterprise Secured A RM30m Manufacturing Contract

Tel : (603) 9280 2162 Analyst : Tan Kam Meng, CFA E-mail: tan.kam.meng@rhb.com.my


- Hai-O, via its wholly-owned subsidiary SG Global Biotech, has secured an exclusive manufacturing contract from Pure Circle, which is a listed company on London Stock Exchange, to manufacture Stevia natural sweetener for the next five years in return for a total minimum guaranteed revenue of RM30m. Stevia natural sweetener is a natural extract from the stevia rebaudiana plant, which is now widely used in food and beverage applications for companies like Cargill and Coca-cola as a sugar substitute with zero calories.
- According to management, there is no significant capex needed to carry out the manufacturing activity as Hai-O's existing plants are already able to produce up to 80 tonnes p.a. of the Stevia natural sweetener for the next 3 years. This would translate into a revenue of RM4-5m p.a.. Thereafter, should demand increase, Hai-O intends to build a new plant which would increase its production capacity to 150 tonnes per year. We were given to understand that the profit margin for producing this product could be higher than its existing manufacturing margin, ie. >30%. We also note that Hai-O could be appointed as an exclusive distributor in Malaysia and China at a later stage to distribute the product. We have not factored in the appointment of Hai-O as the exclusive distributor in Malaysia and China into our earnings forecasts.
- All in, we raise our FY04/09-10 earnings forecasts by 2-3% to reflect: 1) a RM4m p.a. revenue contribution from manufacturing stevia natural sweetener; and 2) higher operating margin for the manufacturing division of 31% from 30%. Correspondingly, indicative fair value is raised to RM4.04/share from RM3.96/share based on unchanged target PE of 10x CY08 EPS, which is at a 40% discount to our CY08 target PE of 16x for the consumer sector, to reflect its smaller earnings base and market capitalisation. Maintain **Outperform**.

Table 1:	Investm	ent Statisti	cs (HAIO	; Code: 766	8)			Bloomberg	Ticker:	HAIO MK
FYE Apr	Revenue	Net Profit	EPS	EPS gwth	PER	C.EPS*	NTA/share	Net gearing	ROE	Net. Div.
	(RMm)	(RMm)	(sen)	(%)	(x)	(sen)	(x)	(x)	(%)	Yld. (%)
2007a	189.3	21.4	26.4*	105.3*	11.4		1.5	Net cash	11.0	3.7*
2008f	294.0	30.1	36.3	37.6	8.3	33.0	1.5	0.0	13.0	4.0
2009f	338.8	35.2	42.4	17.0	7.1	38.0	1.8	Net cash	12.8	4.8
2010f	376.0	38.9	46.9	10.5	6.4	45.0	2.1	Net cash	12.0	5.3
Issued Capital (m shares) 82.6 Major Shareholders								(%)		
Market Capitalisation (RMm) 247.8 Tan Family								25.0		
Daily Trading Volume (m shares) Daily Excellent Communication									5.2	
52-week	Price Rang	e (RM / s)			1.38-3.3	8				

Second Board Listing /Trustee Stock/non-Syariah Approved Stock By The SC

^ Consensus based on IBES Estimates

* Adjusted for bonus issue



IMPORTANT DISCLOSURES

This report has been prepared by RHB Research Institute Sdn Bhd (RHBRI) and is for private circulation only to clients of RHBRI and RHB Investment Bank Berhad (previously known as RHB Sakura Merchant Bankers Berhad). It is for distribution only under such circumstances as may be permitted by applicable law. The opinions and information contained herein are based on generally available data believed to be reliable and are subject to change without notice, and may differ or be contrary to opinions expressed by other business units within the RHB Group as a result of using different assumptions and criteria. This report is not to be construed as an offer, invitation or solicitation to buy or sell the securities covered herein. RHBRI does not warrant the accuracy of anything stated herein in any manner whatsoever and no reliance upon such statement by anyone shall give rise to any claim whatsoever against RHBRI. RHBRI and/or its associated persons may from time to time have an interest in the securities mentioned by this report.

This report does not provide individually tailored investment advice. It has been prepared without regard to the individual financial circumstances and objectives of persons who receive it. The securities discussed in this report may not be suitable for all investors. RHBRI recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. The appropriateness of a particular investment or strategy will depend on an investor's individual circumstances and objectives. Neither RHBRI, RHB Group nor any of its affiliates, employees or agents accepts any liability for any loss or damage arising out of the use of all or any part of this report.

RHBRI and the Connected Persons (the "RHB Group") are engaged in securities trading, securities brokerage, banking and financing activities as well as providing investment banking and financial advisory services. In the ordinary course of its trading, brokerage, banking and financing activities, any member of the RHB Group may at any time hold positions, and may trade or otherwise effect transactions, for its own account or the accounts of customers, in debt or equity securities or loans of any company that may be involved in this transaction.

"Connected Persons" means any holding company of RHBRI, the subsidiaries and subsidiary undertaking of such a holding company and the respective directors, officers, employees and agents of each of them. Investors should assume that the "Connected Persons" are seeking or will seek investment banking or other services from the companies in which the securities have been discussed/covered by RHBRI in this report or in RHBRI's previous reports.

This report has been prepared by the research personnel of RHBRI. Facts and views presented in this report have not been reviewed by, and may not reflect information known to, professionals in other business areas of the "Connected Persons," including investment banking personnel.

The research analysts, economists or research associates principally responsible for the preparation of this research report have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors and firm revenues.

The recommendation framework for stocks and sectors are as follows : -

Stock Ratings

Outperform = The stock return is expected to exceed the KLCI benchmark by greater than five percentage points over the next 6-12 months.

Trading Buy = Short-term positive development on the stock that could lead to a re-rating in the share price and translate into an absolute return of 15% or more over a period of three months, but fundamentals are not strong enough to warrant an Outperform call. It is generally for investors who are willing to take on higher risks.

Market Perform = The stock return is expected to be in line with the KLCI benchmark (+/- five percentage points) over the next 6-12 months.

Underperform = The stock return is expected to underperform the KLCI benchmark by more than five percentage points over the next 6-12 months.

Industry/Sector Ratings

Overweight = Industry expected to outperform the KLCI benchmark, weighted by market capitalisation, over the next 6-12 months.

Neutral = Industry expected to perform in line with the KLCI benchmark, weighted by market capitalisation, over the next 6-12 months.

Underweight = Industry expected to underperform the KLCI benchmark, weighted by market capitalisation, over the next 6-12 months.

RHBRI is a participant of the CMDF-Bursa Research Scheme and will receive compensation for the participation. Additional information on recommended securities, subject to the duties of confidentiality, will be made available upon request.

This report may not be reproduced or redistributed, in whole or in part, without the written permission of RHBRI and RHBRI accepts no liability whatsoever for the actions of third parties in this respect.